Evaluación in vitro de Ticarcilina, Ceftazidima, Piperacilina y la asociación Piperacilina+Tazobactam sobre Pseudomonas aeruginosa intrahospitaloria

Authors

  • Jorge Velásquez Universidad San Martín de Porres
  • Frank Lizaroso Universidad San Martín de Porres
  • Walter Wong Hospital Arzobispo Loayza
  • Hernani Larrea Universidad San Martín de Porres
  • Angel Solazar Hospital Arzobispo Loayza
  • Jervny Paredes Hospital Arzobispo Loayza

Keywords:

Hospital, Pseudomonas aeruginosa, Betalactams antibiotics, Bacterial resistance

Abstract

The objective of this study has been to identify and to classity the antibiophenotypes of resistance to the betalactams in the Pseudomonas aeruginosa strains agaist three antiPseudomonas betalactams and the association of one of these with an inhibitor of betalactamasc.

Seventy non-repetitious strains of Pseudomonas aeruginosa isolated from samples of patients hospitalized by not less than 72 hours were studied. The used antibiograms were diffusion in agar (Kirby Bauer's method) and the minimal inhibitory concentration (MIC) were determined through the technique of the E-test. Finally, the antibiophenotypes of Pseudomonas aeruginosa for the betalactams were and classified.

The results show that 41.1% of strains of Pseudomonas aeruginosa was sensitive to Ticarcilin, while 605 of the strains was sensitive to Piperacilin (alone and in association with Tazobactam). Ceftazidime has a higher activity than Ticarcilin and Piperacilin (70.4% of the sensitive strains).

In conclusion, the percentages of resistance found for Ceftazidime, Ticarcilin, Piperacilin and Piperacilin+Tazobactam invalidate the use of these antibiotics in the probabilistic treatment of an infection due to Pseudomonas aeruginosa. However, a partial recovery of the sensitivity levels is possible for Ceftazidime through the application of certain restrictions.

Downloads

Download data is not yet available.

Published

2001-03-31

Issue

Section

ORIGINAL WORKS

How to Cite

1.
Evaluación in vitro de Ticarcilina, Ceftazidima, Piperacilina y la asociación Piperacilina+Tazobactam sobre Pseudomonas aeruginosa intrahospitaloria. Acta Med Peru [Internet]. 2001 Mar. 31 [cited 2024 Dec. 26];18(1):18-21. Available from: https://amp.cmp.org.pe/index.php/AMP/article/view/1745